EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Precise Activity System for Pharmacogenetics Based on Estimation of CYP2D6 A llelic Percentage Activity from the International CEPAM Database

Fenja Klima iD, Thomas Helland iD, Robin Michelet iD, Anna M Mc Laughlin iD, Jesse J Swen iD, Henk-Jan Guchelaar iD, Fabienne Thomas iD, Melanie White-Koning iD, Ron H N van Schaik iD, Ron H J Mathijssen iD, Werner Schroth iD, Matthias Schwab iD und 5 weitere

Clinical Pharmacology & Therapeutics · 11.11.2026

DOI: 10.1002/cpt.70560 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 11.11.2026. Verfasst von Fenja Klima und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The polymorphic enzyme CYP2D6 contributes to the metabolism of many frequently prescribed drugs, causing substantial variability in drug exposure and treatment outcomes. Genotype‐based dosing recommendations currently rely on drug‐agnostic categorical CYP2D6 allele activity values (AVs), potentially leading to imprecise CYP2D6 phenotype classification and under‐/overdosing of numerous medications. To further advance precision dosing, we developed a CYP2D6 percentage activity ( CYP2D6 ‐PA) framework by estimating CYP2D6 allelic percentage activity ( CYP2D6 ‐APA) from 0% (no activity) to 100% ( CYP2D6*1 ‐normalized reference activity) using tamoxifen and its active metabolite Z‐endoxifen as a model substrate. By leveraging nonlinear mixed‐effects modeling of the international CEPAM database (>7,000 patients from 31 studies), bias‐corrected CYP2D6 ‐APAs were estimated, considering global allele distributions, additional covariates, and limited CYP2D6 genotyping. Estimated CYP2D6 ‐APAs spanned 0%–100%, several deviating substantially from their categorical AVs. In particular, CYP2D6*2 and *35 (normal function, AV = 1), and *17 and *29 (decreased function, AV = 0.5) showed lower CYP2D6 ‐APAs of 64–68% and 29%, respectively. Conversely, CYP2D6*9 (decreased function, AV = 0.25) showed a higher CYP2D6 ‐APA (52%). Each additional allele copy exhibited 68% of the activity of the first copy, less than the twofold increase assumed by AVs. Neglecting limited genotyping (alleles misclassified as reference CYP2D6*1 ), caused CYP2D6 ‐APA overestimation by 1.1‐fold. Using CYP2D6 ‐APAs instead of AVs translated to changes in predicted individual Z‐endoxifen concentrations (−22.3% to 40.0%). While substrate specificity of empirically derived robust tamoxifen CYP2D6 ‐APAs requires evaluation, CYP2D6 ‐PA provides a framework applicable to other substrates/pharmacogenes. Thus, CYP2D6 ‐PA lays the foundation for revising genotype‐to‐phenotype translation systems, improving precision of pharmacogenetics‐guided dosing and optimizing treatment outcomes upon prospective validation.

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany.
  • Graduate Research Training Program PharMetrX, Berlin/Potsdam, Germany.
  • Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.
  • Hormone Laboratory, Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.
  • Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Pharmetheus AB, Uppsala, Sweden.

ORCID-Profile: Fenja Klima, Thomas Helland, Robin Michelet, Anna M Mc Laughlin, Jesse J Swen, Henk-Jan Guchelaar, Fabienne Thomas, Melanie White-Koning, Ron H N van Schaik, Ron H J Mathijssen, Werner Schroth, Matthias Schwab, Gunnar Mellgren, Andrea Gaedigk, Daniel L Hertz, Charlotte Kloft

Zitieren

APA

Klima, F., Helland, T., Michelet, R., Mc Laughlin, A. M., Swen, J. J., Guchelaar, H. J., Thomas, F., White-Koning, M., van Schaik, R. H. N., Mathijssen, R. H. J., Schroth, W., Schwab, M., Mellgren, G., Gaedigk, A., Hertz, D. L., Kloft, C., & CEPAM consortium (2026). A Precise Activity System for Pharmacogenetics Based on Estimation of CYP2D6 A llelic Percentage Activity from the International CEPAM Database. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70560

Vancouver

Klima F, Helland T, Michelet R, Mc Laughlin AM, Swen JJ, Guchelaar HJ, et al. A Precise Activity System for Pharmacogenetics Based on Estimation of CYP2D6 A llelic Percentage Activity from the International CEPAM Database. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70560

BibTeX
@article{Klima2026,
  author = {Klima, Fenja and Helland, Thomas and Michelet, Robin and Mc Laughlin, Anna M and Swen, Jesse J and Guchelaar, Henk-Jan and Thomas, Fabienne and White-Koning, Melanie and van Schaik, Ron H N and Mathijssen, Ron H J and Schroth, Werner and Schwab, Matthias and Mellgren, Gunnar and Gaedigk, Andrea and Hertz, Daniel L and Kloft, Charlotte and CEPAM consortium, CEPAM consortium},
  title = {A Precise Activity System for Pharmacogenetics Based on Estimation of CYP2D6 A llelic Percentage Activity from the International CEPAM Database},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70560}
}
Kostenlos starten →